Northern Trust Corp Makes New $2.77 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Northern Trust Corp bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 159,043 shares of the company's stock, valued at approximately $2,771,000. Northern Trust Corp owned about 0.29% of Bicara Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. increased its stake in shares of Bicara Therapeutics by 171.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after purchasing an additional 1,375,265 shares during the period. Vanguard Group Inc. increased its stake in Bicara Therapeutics by 1,457.9% in the fourth quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock valued at $18,997,000 after acquiring an additional 1,020,528 shares during the last quarter. Geode Capital Management LLC increased its stake in Bicara Therapeutics by 859.4% in the fourth quarter. Geode Capital Management LLC now owns 466,642 shares of the company's stock valued at $8,131,000 after acquiring an additional 418,003 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in Bicara Therapeutics in the fourth quarter valued at approximately $2,731,000. Finally, Alliancebernstein L.P. boosted its position in Bicara Therapeutics by 16.0% in the fourth quarter. Alliancebernstein L.P. now owns 821,264 shares of the company's stock valued at $14,306,000 after buying an additional 113,261 shares in the last quarter.

Analyst Upgrades and Downgrades

BCAX has been the topic of a number of research analyst reports. HC Wainwright cut their target price on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price on the stock in a report on Friday, May 23rd. Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Wedbush reaffirmed an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Trading Down 0.2%

BCAX stock traded down $0.02 during trading on Thursday, reaching $9.44. The stock had a trading volume of 1,042,158 shares, compared to its average volume of 545,425. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $28.09. The company's 50 day moving average is $12.62 and its two-hundred day moving average is $14.56.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). Research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.